Vision Mission & Strength
Quality Policy
Manufacturing Facility
R & D
Management Messages
Business Motto
Doxiva Montiva
Bexen Cefracef Fixpro Nixon Roxcef Roxcef injection Xinarox CV
Metavas MR Nitrogina SR
Tamino ER Tamino Plus
Vermikil
Florocin Revalon Toplevo 500
Azaltic
Diacana Diazid Empa Glucomin Lijenta 5 Lijenta-M
Receca
Anxionil Lyrinex Pandura Thixtra
AMX Halopen
Flurodent
Mesala
Altrip
Nitide
Adarbi Bisopress Losarva Lovapres 5
Mecliz Plus Prokinet
Defungi Symbiotrin
Meroxin
Esotor Gastab Omecron Pansos Rablet
Arcet Fexten Itchlor Rupatid
Visnil
Isosal
Broculyt Erdostin Mucodil Nacsol
Irobest
Oxydrop
Etrib Flexivan Flexivan ER Nimovo Nipoxen Toralin Vurdon SR
Niprolac Oral Sol
D-Star Nipro Gold Oxi-Q Polytamin Starcal Starcal D Starcal D Forte Starcal M V3N V4Z Vegecap-E
Avator Rovator
Reflexen
Cialix Danafil
NIPRO JMI Pharma Ltd. (NJP) is contributing in developing a world-class practicein the pharma industry of Bangladesh by bridling the unment challenges in healthcare sector. It is one of the fastest growing pharmaceutical companies in Bangladesh, started its journey in 2012 with collaboration of NIPRO Corporation; a Japan based giant multinational company, a press release said.
NIPRO JMI Pharma Limited (NJP) has introduced Linagliptin (Lijenta) and Empagliflozin (Empa), which are the breakthroughs in diabetic management and aiding millions of diabetic patients in the country....
NIPRO JMI Pharma Ltd. has celebrated Bangla New Year - 1426 at Corporate office....
Japan Bangladesh joint venture company- NIPRO JMI Pharma held its annual sales conference 2018 at International Convention City, Bashundhara, Dhaka.....
